Mario Mandalà
Impact in
- Internal Medicine top 0.1%
- Venous Thromboembolism Diagnosis and Management
- Oncology top 0.2%
- Cancer Immunotherapy and Biomarkers
- Cutaneous Melanoma Detection and Management
- CAR-T cell therapy research
- Colorectal Cancer Treatments and Studies
Papers in
- Oncology 148
- Cancer Immunotherapy and Biomarkers 62
- Cutaneous Melanoma Detection and Management 47
- CAR-T cell therapy research 44
- Colorectal Cancer Treatments and Studies 20
-
- Melanoma and MAPK Pathways 108
- Co-authors
- Daniela Massi (42 shared papers)Roberto Labianca (22 shared papers)Paolo A. Ascierto (75 shared papers)Anna Falanga (12 shared papers)Claus Garbe (33 shared papers)Fausto Roila (4 shared papers)Stefania Mosconi (4 shared papers)Gabriella Liszkay (26 shared papers)
- Journals
- Annals of Oncology (57 papers)Journal of Clinical Oncology (56 papers)European Journal of Cancer (13 papers)Critical Reviews in Oncology/Hematology (8 papers)The Lancet Oncology (7 papers)
- Partner nations
- ItalyUnited StatesGermany
In The Last Decade
Mario Mandalà
266 papers receiving 11.8k citations
Mario Mandalà's Hit Papers
Peers
Comparison fields: 5 of 127
- Internal Medicine 1.8k
- Oncology 5.8k
- Emergency Medical Services 583
- Immunology 1.6k
- Molecular Biology 4.3k
Countries citing papers authored by Mario Mandalà
This map shows the geographic impact of Mario Mandalà's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mario Mandalà with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mario Mandalà more than expected).
Fields of papers citing papers by Mario Mandalà
This network shows the impact of papers produced by Mario Mandalà. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mario Mandalà. The network helps show where Mario Mandalà may publish in the future.
Co-authors
The 25 scholars most cited alongside Mario Mandalà, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 273 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma Hit paper breakdown → | 2014 | 1506 |
| 2 | Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2013 | 1097 |
| 3 | Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial Hit paper breakdown → | 2018 | 690 |
| 4 | Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study Hit paper breakdown → | 2009 | 452 |
| 5 | Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines Hit paper breakdown → | 2011 | 406 |
| 6 | Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial Hit paper breakdown → | 2018 | 400 |
| 7 | 2017 | 320 | |
| 8 | Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab Hit paper breakdown → | 2016 | 315 |
| 9 | 2016 | 300 | |
| 10 | 1999 | 208 | |
| 11 | Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline Hit paper breakdown → | 2023 | 202 |
| 12 | 2014 | 196 | |
| 13 | 2013 | 137 | |
| 14 | 2014 | 129 | |
| 15 | 2014 | 128 | |
| 16 | 2017 | 127 | |
| 17 | 2009 | 124 | |
| 18 | 2020 | 123 | |
| 19 | 2021 | 121 | |
| 20 | 2022 | 118 |
About Mario Mandalà
Mario Mandalà is a scholar working on Oncology, Molecular Biology, Organic Chemistry, Immunology and Internal Medicine, having authored 273 papers that have together received 12.0k indexed citations. Recurring topics across this work include Melanoma and MAPK Pathways (108 papers), Cancer Immunotherapy and Biomarkers (62 papers), Cutaneous Melanoma Detection and Management (47 papers), CAR-T cell therapy research (44 papers), Venous Thromboembolism Diagnosis and Management (30 papers), Click Chemistry and Applications (29 papers), Immunotherapy and Immune Responses (22 papers) and Colorectal Cancer Treatments and Studies (20 papers). The work is most often cited by research in Internal Medicine (1.8k citations), Oncology (5.8k citations), Emergency Medical Services (583 citations), Immunology (1.6k citations) and Molecular Biology (4.3k citations). Mario Mandalà has collaborated with scholars based in Italy, United States and Germany. Frequent co-authors include Daniela Massi, Roberto Labianca, Paolo A. Ascierto, Anna Falanga, Claus Garbe, Fausto Roila, Stefania Mosconi, Gabriella Liszkay, Caroline Dutriaux and Andrés Cervantes. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, European Journal of Cancer, Critical Reviews in Oncology/Hematology and The Lancet Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.